OptiBiotix Health PLC Distribution Agreement for SlimBiome® in Thailand (8721Y)
14 Mayo 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8721Y
OptiBiotix Health PLC
14 May 2019
OptiBiotix Health plc
("OptiBiotix")
Distribution Agreement for SlimBiome(R) in Thailand
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces it has entered into a three
year distribution agreement with Primo Trading Co., Ltd ("Primo")
to exclusively distribute and commercialise OptiBiotix's
SlimBiome(R) and SlimBiome(R) containing ingredients in
Thailand.
The agreement grants Primo exclusive distribution in Thailand in
return for meeting annual sales targets to maintain exclusivity.
Primo's commitment to purchase a minimum of 500kg in the first 12
months rising to 5,000kg in the third year, reflects its confidence
in SlimBiome(R) from its pre-launch sales forecasts and includes a
100kg initial purchase order on signing this agreement. Primo is a
national distributor of specialised food ingredients to a broad
range of manufacturers in the nutraceutical, pharmaceutical and
supplement industries based on strong customer relationships.
This agreement follows on from the recent FSSAI approval gained
by OptiBiotix's partner, Zeon Life Sciences, for the manufacturing
of SlimBiome(R) and SlimBiome(R) containing ingredients in India to
supply the Asian markets (RNS: 11 April 2019).
Thailand is experiencing an obesity wave with one in three men
and 40% of women now classified obese. The country is now the
second heaviest in Asia after Malaysia, mainly as a result of
increasing fast food outlets and high sugar usage throughout the
food industry.
Christina Wood, Sales & Marketing Director, commented: "We
are pleased to announce this exclusive distribution deal and sales
order with such a well-established national distributor of
high-quality ingredients in Thailand. Achieving FSSAI approval for
the manufacturing of SlimBiome(R) in India enables us to reach and
service the increasing demand from the Asian countries as part of
our expanding commercialisation strategy. The growing obesity
crisis has opened up an opportunity in these markets for
SlimBiome(R) where food supplements and functional holistic
products are readily accepted. The value gained from our industry
awards, clinical studies and recent medical device approval has
given our products clear differentiation over other weight loss
products. The team at Primo have already identified key areas for
SlimBiome(R) and are in the process of formulating SlimBiome(R)
containing products to meet local tastes."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTBUGDUDXBBGCX
(END) Dow Jones Newswires
May 14, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024